Skip to main content
Clinical Trials/NCT03590769
NCT03590769
Completed
Phase 1

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

University of California, San Francisco2 sites in 1 country9 target enrollmentJune 1, 2017

Overview

Phase
Phase 1
Intervention
18F-FDG
Conditions
Peripheral Arterial Disease
Sponsor
University of California, San Francisco
Enrollment
9
Locations
2
Primary Endpoint
Changes found in the quantitative measure of FDG-PET uptake at intervention site prior to and after peripheral vascular injury.
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study evaluates the local inflammatory and resolution response of patients undergoing peripheral vascular intervention like an angioplasty of the superficial femoral artery (SFA) or popliteal artery, or stenting of the iliac artery or SFA, through the use of Positron emission tomography-magnetic resonance imaging (PET/MRI). PET/MRI will be performed prior to intervention, one day and one week after intervention.

Detailed Description

Magnetic resonance imaging (MRI) imaging allows for non-invasive visualization of anatomical structures while Positron emission tomography (PET) scans allow for the observation of molecular and cellular activities. Using a PET/MRI in patients with vascular injury post intervention with help evaluate the vascular inflammatory and resolution response in vivo. Acute vascular injury through endovascular intervention results in recruitment of inflammatory cells such as macrophages to the vessel wall. Macrophages are very metabolically active and consume glucose at a high rate. In PET/MRI, subjects are injected with 18F-Fluorodeoxyglucose (18F-FDG), a radioactively labeled glucose molecule which is consumed by macrophages. When 18F-FDG is consumed, it is retained within macrophages more avidly than other atherosclerotic lesion elements. Thus, FDG-PET provides a unique and noninvasive approach to quantitatively measure macrophage activity at the intervention site. This study will provide key pilot data for developing an imaging surrogate endpoint for pro-resolving mediator treatment intervention trials going forward.

Registry
clinicaltrials.gov
Start Date
June 1, 2017
End Date
September 3, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Over the age of 40,
  • With resting or exercise ABI \<0.9, TBI \<0.6
  • Have claudication or limb threatening ischemia \& planning to undergo a percutaneous angioplasty of SFA or popliteal artery, or stenting of the iliac artery or SFA.

Exclusion Criteria

  • Evidence of active infection
  • Hypersensitivity or allergy to contrast agents
  • Chronic liver disease, renal disease (GFR\< 30) or chronic inflammatory disorders
  • Insulin dependent diabetes
  • Presence of metal within subject's body, pacemakers, or defibrillators
  • BMI \< 20 or \>35
  • Recent other major surgery or illness within 30 days
  • Use of immunosuppressive medications or steroids
  • History of organ transplantation
  • Pregnancy, or plans to become pregnant, or lactating

Arms & Interventions

PET/MR using FDG-18 radiotracer

Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.

Intervention: 18F-FDG

Outcomes

Primary Outcomes

Changes found in the quantitative measure of FDG-PET uptake at intervention site prior to and after peripheral vascular injury.

Time Frame: 1 time each week for 3 weeks

Patient is given 18F-FDG radio tracer. The tracer is quantitatively measured through FDG-PET imaging modality for uptake at the intervention site.

Secondary Outcomes

  • Changes in the correlating the inflammatory and resolution response prior to and after peripheral vascular injury.(1 time each week for 3 weeks)

Study Sites (2)

Loading locations...

Similar Trials